

## Important notice and disclaimer



This document is a presentation prepared by Pacific Smiles Group Limited (ACN 103 087 449) (**Pacific Smiles**).

Material in this presentation provides general background information about the activities of Pacific Smiles current at the date of this presentation, unless otherwise noted. Information in this presentation remains subject to change without notice. Circumstances may change and the contents of this presentation may become outdated as a result.

The information contained in this presentation is a summary only and does not purport to be complete. It should be read in conjunction with Pacific Smiles' other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offer document under Australian law or the law of any other jurisdiction. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial or tax situation or needs of any particular investor. Readers should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek independent legal, taxation and other professional advice appropriate for their jurisdiction and individual circumstances.

This presentation is not and should not be considered as an offer or recommendation with respect to the subscription for, purchase or sale of any security and neither this document, nor anything in it shall form the basis of any contract or commitment. Accordingly, no action should be taken on the basis of, or in reliance on, this presentation. In particular, this presentation does not

constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. No securities of Pacific Smiles have been, and nor will they be, registered under the Securities Act of 1933 as amended (US Securities Act). Securities in Pacific Smiles may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, registration under the US Securities Act and applicable US state securities laws.

Pacific Smiles, its related bodies corporate and any of their respective officers, directors, employees, agents or advisers (Pacific Smiles Parties), do not make any representation or warranty, express or implied, in relation to the accuracy, reliability or completeness of the information contained herein, and to the maximum extent permitted by law disclaim any responsibility and liability flowing from the use of this information by any party. To the maximum extent permitted by law, the Pacific Smiles Parties do not accept any liability to any person, organisation or entity for any loss or damage arising from the use of this presentation or its contents or otherwise arising in connection with it.

#### Forward looking statements

This document contains certain forward looking statements and comments about expectations about the performance of its businesses. Forward looking statements can generally be identified by the use of forward looking words such as, without limitation, 'expect', 'outlook', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'would', 'believe', 'forecast', 'estimate', 'target' and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance on, future earnings or financial position or performance are also forward looking statements.

Forward looking statements involve inherent risks and

uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward looking statements will not be achieved. Forward looking statements are provided as a general guide only. and should not be relied on as an indication or guarantee of future performance. Forward looking statements involve known and unknown risks, uncertainty and other factors. and may involve significant elements of subjective judgment and assumptions as to future events which may or may not prove to be correct, which can cause Pacific Smiles' actual results to differ materially from the plans. objectives, expectations, estimates and intentions expressed in such forward looking statements and many of these factors are outside the control of Pacific Smiles. As such, undue reliance should not be placed on any forward looking statement. Past performance is not a guide to future performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward looking statements, forecast financial information or other forecast. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of Pacific Smiles, Pacific Smiles does not undertake any obligation to update or review any forwardlooking statements (other than to the extent required by applicable law).

#### Pro forma financial information

Pacific Smiles uses certain measures to manage and report on its business that are not recognised under Australian Accounting Standards. These measures are referred to as pon-IFRS financial information.

Pacific Smiles considers that this non-IFRS financial information is important to assist in evaluating Pacific Smiles' performance. The information is presented to assist in making appropriate comparisons with prior

periods and to assess the operating performance of the business. For a reconciliation of the non-IFRS financial information contained in this presentation to IFRS-compliant comparative information, refer to the Appendices of this presentation.

All dollar values are in Australian dollars (A\$) unless otherwise stated.

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.





**Phil McKenzie** 

Managing Director and Chief Executive Officer



**Allanna Ryan** 

**Chief Financial Officer** 

# Our True Purpose

To improve the oral health of ALL Australians to world's best.

Our Patients Trust us

Our Dentists are Respected by us

Our Employees Matter to us





# H1 2021 Highlights

\$121.7m

**PATIENT FEES - UP 15.5%** 

13.2%

**SAME CENTRE GROWTH - UP 380 bps** 

\$10.4m

**UNDERLYING NPAT – UP 106.6%** 

102

**DENTAL CENTRES – UP 9.7%** 

\$21.2m

**UNDERLYING EBITDA – UP 64.7%** 

**2.4cps** 

**ORDINARY DIVIDENDS - UNCHANGED** 



# **Operational snapshot**





















# **Strong Growth Track Record**





#### Notes:

FY2020 impacted by government mandated dental restrictions due to COVID-19



## **COVID-19 Update**



Trend of patients moving from CBD centres to suburban centres due to many working from home



Centres in Victoria were impacted by restrictions imposed during the 2<sup>nd</sup> wave. All centres remained open during this time



Training sessions and focused appreciation for employees



Increased debt facility to provide protection against future waves



Targeted marketing in states outside VIC during 2<sup>nd</sup> wave



Sustained extra COVID-19 measures above already stringent standards





# **Summary Income Statement**




#### For the half year ended 31 December 2020

\$ MILLIONS	UNDERLYING <sup>1</sup> H1 2021	UNDERLYING <sup>1</sup> H1 2020	CHANGE
Revenue	78.4	68.3	14.9%
Gross profit	72.6	62.2	16.7%
EBITDA	21.2	12.9	64.7%
Depreciation and amortisation	(5.7)	(5.4)	(6.2%)
EBIT	15.5	7.5	106.4%
Net interest expense	(0.3)	(0.4)	17.8%
Profit before tax	15.2	7.2	112.7%
Tax	(4.8)	(2.1)	(127.1%)
Net profit after tax	10.4	5.0	106.6%
Key operating metrics			
Number of Dental Centres	102	93	9.7%
Number of Commissioned Dental Chairs	411	373	10.2%
Patient Fees (\$m)	121.7	105.4	15.5%
Same Centre Patient Fees growth	13.2%	9.4%	
Key financial metrics			
Earnings per share (cents)	6.8	3.3	
EBITDA margin	27.1%	18.9%	
EBITDA to Patient Fees margin	17.4%	12.2%	
EBIT margin	19.8%	11.0%	

- Patient fees up 15.5% with Same Centre Patient Fee growth of 13.2% (H1 2020: 9.4%) due to strong growth in average fees per appointment and number of appointments attended in majority of cohorts
- Underlying EBITDA up 64.7% to \$21.2 million (H1 2020: \$12.9m) due to strong patient fee growth, efficiency gains in labour utilisation and JobKeeper scheme
- The JobKeeper scheme provided \$8.0m in gross benefits. The approximate benefit, net of COVID-19 related EBITDA impacts is \$3.6m. JobKeeper benefit allowed us to service patients across communities and support employees in COVID-19 restricted centres
- D&A increased by \$0.3 million reflecting the reduced number of new centre developments in FY 2020

# H1 2021 EBITDA Bridge






- The key drivers of the movements are summarised in the adjacent chart:
  - Same centres performed strongly with patient fee growth of 13.2% (H1 2020 9.4%) and strong EBITDA margin growth given an increase in average fees per appointment and efficiencies gained through improved labour utilisation
  - FY 2020 new centres performed inline with expectations, achieving profit in H1 2021
  - Start up losses from new centres opened in H1 2021 8 new centres were opened (H1 2020: 4)
  - Jobkeeper provided an estimated benefit of \$3.6m, net of COVID-19 related EBITDA impacts. Pacific Smiles entitlement to the JobKeeper program ceased on 30 September 2020

# H1 2021 EBITDA Margin Bridge





- Same centre margin expansion driven by an increase in average fees per appointment, improved labour utilisation, and margin expansion as centres ramp to maturity and leverage fixed cost base
- Centre mix impacted by increasing proportion of fees coming from new centres opened in the last 2 years which generate lower margins than mature centres
- Corporate costs improved as a percentage of patient fees, moving from 6.8% H1 2020 to 6.1% H1 2021. This is due to carrying vacant positions in H1 2021, which is expected to unwind in H2 2021

#### H1 2021 Cashflow & Balance Sheet



REPORTED <sup>3</sup>	REPORTED <sup>3</sup>
H1 2021	H1 2020
20.3	12.1
0.9	0.2
6.0	2.7
(0.3)	(0.4)
(4.0)	(2.5)
22.9	12.0
(11.1)	(6.9)
-	-
-	-
(11.1)	(6.9)
(19.0)	3.5
-	-
-	(5.3)
(19.0)	(1.8)
(7.2)	3.3
	H1 2021  20.3  0.9  6.0  (0.3)  (4.0)  22.9  (11.1)  (19.0)  -  (19.0)

\$ MILLIONS	REPORTED <sup>3</sup> 31 DEC 2020	
Cash and cash equivalents	8.0	10.3
Other current assets	6.7	6.1
Property, plant and equipment	56.3	55.5
Other assets	18.0	16.9
Total Assets	89.0	88.7
Payables	21.7	15.8
Provisions	13.6	12.7
Borrowings	3.0	20.5
Total Liabilities	38.3	49.0
Net Assets	50.7	39.7

- Strong EBITDA cash conversion<sup>1</sup> of 134%
- The non-cash item includes impairment of assets and share based payments
- Change in working capital includes the receipt of outstanding JobKeeper at June 2020
- Net capital expenditure of \$11.1m, including:
  - New centres (\$6.4m);
  - Bulk purchase of dental chairs (\$1.1m);
  - Scanners (\$1.1m)
- H1 2021 interim dividend of 2.4cps, unchanged from H1 2020
- Increases in property, plant and equipment reflects a greater number of new centres in H1 2021
- Borrowings decreased due to pay down of debt from free cashflow in H1 2021

#### Notes

- 1. Cash conversion calculated as operating cash flow excluding tax and net finance cost as a ratio of EBITDA (Statutory excluding AASB16)
- 2. Amounts in the table have been rounded to the nearest \$100,000. Any discrepancies between the totals and sums of components are due to rounding
- 3. Reported is Statutory excluding the impact of AASB 16



# **Our Long Term Strategy**



Stretch our advantage as the leading Dentist Service Organisation in Australia

# **NETWORK GROWTH**

- **Existing Centres**
- Commission chairs in existing surgeries
- Greenfields New Centres
- Range of Services
- Explore accelerated New Centre roll out





- High functioning leadership
- Employee capability building
- Culture Playbook
- LIFT mentoring program and leadership development





- New patient engagement and retention
- Technology centric
- Cost and contract review program
- Process and system optimisation






- Smiles Care Kiosks
- HBF Partnership
- **Digital Scanners**
- New geographies
- New dentist services



### **Network Growth**


# PACIFIC SMILES GROUP

#### **Existing Centres**



COMD-19 restrictions impacted same centre patient fee growth in FY 2020





	Same Centre Patient Fee Growth	H1 2	H1 2020		021
		%	%	%	%
		Growth	Of Total	Growth	Of Total
Same Centre Patient Fee	Centres opened 2010 and earlier	4.8%	50.3%	7.4%	45.9%
Growth	Centres opened 2011 to 2019 <sup>1</sup>	14.1%	49.7%	18.1%	54.1%
	Group	9.4%		13.2%	

Industry leading operations positioned centres to capitalise on strong patient demand

#### **H2 2021 Focus**









Progressing the HBF partnership with the opening of 3 HBFD centres



Exploring an accelerated new centre roll-out program



Engaging with practitioners through new bespoke services and education

#### FY 2021 Guidance - Revised



(Excludes the impact of AASB16 Leases)

PATIENT FEES<sup>1</sup>

Approximately 25 -30% growth YOY

REVISED

NEW DENTAL CENTRES<sup>2</sup>

Approximately 15 centres

**REVISED** 

(Underlying)

Approximately 40 - 50% growth YOY DIVIDEND PAYOUT RATIO

70% - 100% of NPAT

Same centre 411) patient fee growth approximately 13,1%

#### Notes:

- 1. Same centre patient fee growth is approximately 13.1% as at 12th February 2021
- 2. 8 new centres open this first half FY21 and 7 committed for H2 FY21. New dental centres is revised from approximately 14 centres. Target excludes HBFD centres.
- 3. Underlying EBITDA is revised from 35 45% growth YOY



## **Dental centre locations**



#### NSW

QLD



Balgowlah Bateau Bay Baulkham Hills Belmont Relrose Bondi Junction\*\* Blacktown Brookvale Campbelltown Charlestown nib Chatswood Frina nib Erina Figtree Forster

Asplev Birtinya Bribie Island Brisbane CBD **Browns Plains** Buddina **Burleigh Heads** Capalaba Cleveland\*\* **Deception Bay** Helensvale Mitchelton\* Morayfield Mt Gravatt Mt Ommanev North Lakes Redbank Plains Robina\* Runaway Bay Strathpine Victoria Point\*\*

Gladesville Glendale\*\* nib Glendale Greenhills Greenhills Ortho\*\*

Jesmond Kotara Lake Haven Lane Cove\*\* Marrickville Morisset Mount Hutton Narellan nib Newcastle nib North Parramatta Nowra

VIC

Bairnsdale

Caroline Springs

Cranbourne Park

Chirnside Park

Glen Waverley

Greensborough

Keysborough

Ocean Grove\*

Bendigo

Drysdale

Epping\* Glen Iris Parramatta Penrith Queanbevan Raymond Terrace\*\* Rutherford Salamander Bay Shellharbour<sup>‡</sup> Singleton nib Sydney Toronto Town Hall Tuggerah Tweed Heads Waqqa Waqqa Wollongong\*\*

nib Wollongong

Point Cook Preston Ringwood Sale Torquay Traralgon Warragul Waurn Ponds Werribee

#### **ACT**

Belconnen Gungahlin Manuka Tuggeranong Woden nib Woden

Leopold Melbourne nib Melbourne Melton Mill Park Mulgrave Narre Warren\*

## **AASB 16 Leases**



#### Impact of AASB 16 Leases at 31 December 2020

#### **Profit and Loss**

- EBITDA impact increase of \$6.3m
- NPAT impact reduction of \$0.1m

#### **Balance Sheet**

- · Recognition of right of use asset and lease liability
- Total Assets increase by \$58.3m
- Total Liabilities increase by \$62.2m
- Net Asset impact reduction of \$3.8m
- Retained Earnings reduction of \$3.8m

# Adoption date and comparatives

- AASB 16 was adopted from 1 July 2019
- H1 2021 Investor Presentation is presented excluding the impacts of AASB16, with reconciliations to the new accounting standards

# **Underlying Results Reported With AASB16**



#### Reconciliation

	UNDERLYING EXC. AASB16	AASB16 ADJ	UNDERLYING	UNDERLYING EXC. AASB16	AASB16 ADJ	UNDERLYING	UNDERLYING EXC. AASB16	AASB16 ADJ	UNDERLYING
\$ MILLIONS	H1 2021	H1 2021	H1 2021	H1 2020	H1 2020	H1 2020	FY 2020	FY 2020	FY 2020
Revenue	78.4	-	78.4	68.3	-	68.3	120.6	-	120.6
Direct expenses	(5.8)	-	(5.8)	(6.1)	-	(6.1)	(10.6)	-	(10.6)
Gross profit	72.6	-	72.6	62.2	-	62.2	109.9	-	109.9
Other income	8.4	0.2	8.2	0.6	0.2	0.5	2.6	0.4	2.3
Expenses									
Employee expenses	(36.0)	-	(36.0)	(29.8)	-	(29.8)	(48.9)	-	(48.9)
Consumable supplies expenses	(7.0)	-	(7.0)	(5.2)	-	(5.2)	(9.2)	-	(9.2)
Occupancy expenses	(7.9)	(6.4)	(1.4)	(7.1)	(5.9)	(1.3)	(14.8)	(11.9)	(2.8)
Marketing expenses	(1.5)	-	(1.5)	(1.1)	-	(1.1)	(1.9)	-	(1.9)
Administration and other expenses	(7.4)	0.0	(7.4)	(6.7)	(0.1)	(6.6)	(14.2)	(0.1)	(14.1)
EBITDA	21.2	(6.3)	27.5	12.9	(5.8)	18.6	23.5	(11.7)	35.1
Depreciation and amortisation	(5.7)	4.9	(10.5)	(5.4)	4.5	(9.8)	(11.0)	9.0	(20.0)
EBIT	15.5	(1.5)	17.0	7.5	(1.3)	8.8	12.5	(2.6)	15.1
Net finance costs	(0.3)	1.4	1.7	(0.4)	1.4	(1.7)	(0.7)	2.8	(3.5)
Profit before tax	15.2	(0.1)	15.3	7.2	0.1	7.1	11.8	0.1	11.6
Income tax expense	(4.8)	0.0	4.9	(2.1)	0.3	(2.4)	(3.7)	(0.0)	(3.7)
Net profit after tax	10.4	(0.1)	10.4	5.0	0.4	4.6	8.1	0.1	8.0
Key financial metrics									
Earnings per share (cents)	6.8			3.3			5.3		
EBITDA margin	27.1%			18.9%			19.5%		
EBITDA to Patient Fees margin	17.4%			12.2%			12.6%		
EBIT margin	19.8%			11.0%			10.3%		

## **Underlying to Statutory Reconciliation**



#### **Profit and Loss**

	UNDERLYING	ADJ'S	STATUTORY	UNDERLYING	ADJ'S	STATUTORY
\$ MILLIONS	H1 2021	H1 2021	H1 2021	H1 2020	H1 2020	H1 2020
Revenue	78.4	-	78.4	68.3	(0.4)	67.9
Direct expenses	(5.8)	-	(5.8)	(6.1)	-	(6.1)
Gross profit	72.6	-	72.6	62.2	(0.4)	61.8
Other income	8.4	(0.2)	8.2	0.6	(0.2)	0.5
Expenses						
Employee expenses	(36.0)	(0.2)	(36.2)	(29.8)	(0.2)	(30.0)
Consumable supplies expenses	(7.0)	-	(7.0)	(5.2)	-	(5.2)
Occupancy expenses	(7.9)	6.4	(1.4)	(7.1)	5.8	(1.4)
Marketing expenses	(1.5)	-	(1.5)	(1.1)	-	(1.1)
Administration and other expenses	(7.4)	(0.8)	(8.2)	(6.7)	(0.0)	(6.7)
EBITDA	21.2	5.3	26.6	12.9	5.0	17.9
Depreciation and amortisation	(5.7)	(4.9)	(10.5)	(5.4)	(4.5)	(9.8)
EBIT	15.5	0.5	16.1	7.5	0.5	8.0
Net finance costs	(0.3)	(1.4)	(1.7)	(0.4)	(1.4)	(1.7)
Profit before tax	15.2	(0.8)	14.4	7.2	(0.9)	6.3
Income tax expense	(4.8)	0.3	(4.6)	(2.1)	(0.1)	(2.2)
Net profit after tax	10.4	(0.6)	9.8	5.0	(1.0)	4.1
Key financial metrics						
Earnings per share (cents)	6.8			3.3		
EBITDA margin	27.1%			18.9%		
EBITDA to Patient Fees margin	17.4%			12.2%		
EBIT margin	19.8%			11.0%		

- Adjustments to the H1 2021 Income Statement remove the impacts of onceoff Everything Denture asset impairment, executive LTI plan, and reallocation of JobKeeper from other income to employee expenses. In addition, underlying excludes the impact of AASB 16
- Adjustments to the H1 2020 Income Statement remove the impacts of onceoff IT network outage, severance expense, centre relocation, and executive LTI plan expense

# **Reported to Statutory Reconciliation**



#### Balance Sheet as at 31 December 2020

	REPORTED <sup>2</sup>	AASB 16	STATUTORY	REPORTED <sup>2</sup>	AASB 16	STATUTORY
\$ MILLIONS	31 DEC 2020	31 DEC 2020	31 DEC2020	31 DEC 2019	31 DEC 2019	31 DEC 2019
Current Assets						
Cash and cash equivalents	8.0	-	8.0	10.3	-	10.3
Receivables	1.5	0.3	1.8	1.4	0.4	1.7
Current Tax Receivable	-	-	-		-	-
Inventories	4.4	-	4.4	3.8	-	3.8
Other	0.8	-	0.8	0.9	-	0.9
Total Current Assets	14.7	0.3	15.0	16.4	0.4	16.7
Non-Current Assets						
Receivables	-	0.1	0.1	0.0	0.4	0.4
Property, plant and equipment	56.3	56.3	112.5	55.5	53.0	108.5
Intangible assets	10.2	-	10.2	10.9	-	10.9
Deferred tax assets	7.8	1.6	9.5	6.0	2.0	8.0
Total Non-Current Assets	74.3	58.0	132.3	72.4	55.4	127.8
Total Assets	89.0	58.3	147.3	88.7	55.8	144.5
Current Liabilities						
Payables	19.1	(0.0)	19.1	14.5	-	14.5
Lease Liabilities	-	11.0	11.0	-	9.5	9.5
Current Tax Liabilities	2.6	-	2.6	1.3	-	1.3
Provisions	5.3	(0.6)	4.7	4.4	(0.3)	4.1
Total Current Liabilities	27.0	10.3	37.3	20.2	9.3	29.5
Non-Current Liabilities						
Payables	-	-	-	-	-	-
Lease Liabilities	-	56.8	56.8	-	55.2	55.2
Borrowings	3.0	-	3.0	20.5	-	20.5
Provisions	8.3	(5.0)	3.4	8.3	(5.2)	3.2
Total Non-Current Liabilities	11.3	51.9	63.2	28.8	50.1	78.9
Total Liabilities	38.3	62.2	100.5	49.0	59.3	108.4
Net Assets	50.7	3.8	46.8	39.7	(3.6)	36.1
EQUITY						
Contributed equity	36.8	-	36.8	35.1	-	35.1
Reserves	7.9	(3.8)	4.1	3.8	(3.6)	0.3
Retained profits	6.0	(0.0)	6.0	0.8	-	0.8
Total Equity	50.7	(3.8)	46.8	39.7	(3.6)	36.1

<sup>1.</sup> Amounts in the table have been rounded to the nearest \$100,000. Any discrepancies between the totals and sums of components are due to rounding

# **Reported to Statutory Reconciliation**



#### Cashflow as at 31 December 2020

	REPORTED <sup>2</sup>	AASB 16	STATUTORY	REPORTED <sup>2</sup>	AASB 16	STATUTORY
\$ MILLIONS	H1 2021	H1 2021	H1 2021	H1 2020	H1 2020	H1 2020
EBITDA	20.3	6.3	26.6	12.1	5.8	17.9
Other non-cash items	0.9	-	0.9	0.2	-	0.2
Changes in working capital (exc. Income tax)	6.0	(1.0)	5.0	2.7	(0.7)	2.0
Net interest paid	(0.3)	(1.4)	(1.7)	(0.4)	(1.4)	(1.7)
Income tax paid	(4.0)	-	(4.0)	(2.5)	0.1	(2.5)
Net cash flow from operating activities	22.9	3.9	26.8	12.0	3.7	15.7
Net capital expenditure	(11.1)	-	(11.1)	(6.9)	-	(6.9)
Business acquisitions	-	-	-	-	-	-
Lease payments received from finance leases	-	0.2	0.2	-	0.2	0.2
Net cash flow from investing activities	(11.1)	0.2	(11.0)	(6.9)	0.2	(6.7)
Borrowings (net)	(19.0)	-	(19.0)	3.5	-	3.5
Payment of lease liabilities	-	(4.1)	(4.1)	-	(3.9)	(3.9)
Dividends	-	-	<u> </u>	(5.3)	-	(5.3)
Net cash flow from financing activities	(19.0)	(4.1)	(23.1)	(1.8)	(3.9)	(5.7)
Net cash flow	(7.2)	0.0	(7.2)	3.3	0.0	3.3

PACIFIC SMILES H1 2021 RESULTS 25 1. Amounts in the table have been rounded to the nearest \$100,000. Any discrepancies between the totals and sums of components are due to rounding

<sup>2.</sup> Reported is Statutory excluding the impact of AASB 16

